Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck

Leung, Henry W.C.; Lang, Hui Chu; Wang, Shyh Yau; Leung, John; Chan, Agnes L. F.

doi:10.1080/14737167.2021.1890585

Cited by 5 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Literature [25,[63][64][65], clinical data [24,25,63] and our immunohistochemistry staining of patient tissue microarray show that EGFR is an excellent surface receptor in human [66][67][68] and mouse [69][70][71] TNBCs. For example, the anti-EGFR cetuximab and panitumumab are used in clinic to treat head and neck cancer [72][73][74] and colorectal cancer [75][76][77]. Moreover, the cetuximab mediates antibody-dependent cell cytotoxicity (ADCC) in the intratumoral space and primes adaptive and innate cellular immunity [78].…”

Section: Discussionmentioning

confidence: 99%

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer

Zhang

Ngo

et al. 2021

Cancers

View full text Add to dashboard Cite

Triple-negative breast cancers (TNBCs) are highly aggressive and recurrent. Standard cytotoxic chemotherapies are currently the main treatment options, but their clinical efficacies are limited and patients usually suffer from severe side effects. The goal of this study was to develop and evaluate targeted liposomes-delivered combined chemotherapies to treat TNBCs. Specifically, the IC50 values of the microtubule polymerization inhibitor mertansine (DM1), mitotic spindle assembly defecting taxane (paclitaxel, PTX), DNA synthesis inhibitor gemcitabine (GC), and DNA damage inducer doxorubicin (AC) were tested in both TNBC MDA-MB-231 and MDA-MB-468 cells. Then we constructed the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) tagged liposomes and confirmed its TNBC cell surface binding using flow cytometry, internalization with confocal laser scanning microscopy, and TNBC xenograft targeting in NSG female mice using In Vivo Imaging System. The safe dosage of anti-EGFR liposomal chemotherapies, i.e., <20% body weight change, was identified. Finally, the in vivo anti-tumor efficacy studies in TNBC cell line-derived xenograft and patient-derived xenograft models revealed that the targeted delivery of chemotherapies (mertansine and gemcitabine) can effectively inhibit tumor growth. This study demonstrated that the targeted liposomes enable the new formulations of combined therapies that improve anti-TNBC efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer

Zhang

Ngo

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…The literature [ 45 , 53 , 54 , 55 ] and our immunohistochemistry staining of GBM patient tissue microarray show that EGFR or EGFRvIII is overexpressed in more than 40% GBM patients. The chimeric anti-EGFR mAb, Cetuximab, has been approved by the U.S FDA and used to treat head and neck cancer [ 56 , 57 ] and colorectal cancer [ 58 , 59 ]. The therapies to target EGFR signaling pathways have limited clinical benefits in GBM treatment [ 60 , 61 , 62 ], but EGFR has been demonstrated as a good surface target, and the anti-EGFR mAb or peptide can direct the targeted delivery of therapies to GBM [ 45 , 63 , 64 , 65 , 66 ].…”

Section: Discussionmentioning

confidence: 99%

Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma

Chen

Guan

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Glioblastomas, accounting for approximately 50% of gliomas, comprise the most aggressive, highly heterogeneous, and malignant brain tumors. The objective of this study was to develop and evaluate a new targeted therapy, i.e., highly potent natural compound verrucarin A (Ver-A), delivered with monoclonal antibody-directed extracellular vesicle (mAb-EV). First, the high surface expression of epidermal growth factor receptor (EGFR) in glioblastoma patient tissue and cell lines was confirmed using immunohistochemistry staining, flow cytometry, and Western blotting. mAb-EV-Ver-A was constructed by packing Ver-A and tagging anti-EGFR mAb to EV generated from HEK293F culture. Confocal microscopy and the In Vivo Imaging System demonstrated that mAb-EV could penetrate the blood–brain barrier, target intracranial glioblastoma xenografts, and deliver drug intracellularly. The in vitro cytotoxicity study showed IC50 values of 2–12 nM of Ver-A. The hematoxylin and eosin staining of major organs in the tolerated dose study indicated minimal systemic toxicity of mAb-EV-Ver-A. Finally, the in vivo anti-tumor efficacy study in intracranial xenograft models demonstrated that EGFR mAb-EV-Ver-A effectively inhibited glioblastoma growth, but the combination with VEGF mAb did not improve the therapeutic efficacy. This study suggested that mAb-EV is an effective drug delivery vehicle and natural Ver-A has great potential to treat glioblastoma.

show abstract